Find uplifting stories about heroes, innovations, and solutions
28 results for "ptsd treatment"
A groundbreaking treatment that could prevent PTSD before it takes hold just cleared a major regulatory hurdle. The FDA has approved human trials for RST-101, a drug designed to stop trauma from becoming chronic psychological distress.
The Department of Veterans Affairs is testing MDMA-assisted therapy to treat veterans struggling with both PTSD and alcohol addiction, marking a new chapter in mental health care. This trial joins 19 other VA studies exploring how psychedelic treatments could help those traditional methods haven't reached.
A new AI platform called Lucy is solving a critical shortage in psychedelic therapy by training facilitators using real-world data from thousands of support calls. Built from a database of actual psychedelic experiences, Lucy helps prepare therapists for the emotional challenges of guiding patients through breakthrough mental health treatments.
A shipping container with three mobile floatation tanks is heading to Maui to help survivors of the 2023 wildfires that left thousands struggling with PTSD and anxiety. If successful, these spa-like therapy pods could become standard equipment in disaster zones worldwide.
A single treatment with ibogaine, a powerful plant-based compound, helped 30 special forces veterans significantly reduce their PTSD symptoms in a Stanford University study. The promising results offer new hope for military veterans struggling with trauma and mental health challenges.
A groundbreaking trial shows military veterans experiencing dramatic improvements in PTSD symptoms after just one session with ibogaine, a powerful natural psychedelic. The research could open new doors for millions struggling with treatment-resistant trauma.
The FDA is accelerating breakthrough psychedelic therapies for treatment-resistant depression, PTSD, and alcohol use disorder after a presidential directive. Veterans and millions struggling with serious mental illness could gain access to promising new options backed by rigorous science.
President Trump signed an executive order to expand access to psychedelic therapies for conditions like PTSD, depression, and addiction. The move signals growing mainstream acceptance of treatments once considered fringe medicine.
A presidential order is accelerating research on ibogaine, a plant-based treatment showing promise for veterans with PTSD and people battling depression. The FDA says approval could come within months instead of years.
A new executive order accelerates research into psychedelic medicines for mental illness, prioritizing veterans facing treatment-resistant PTSD and depression. The move ends decades of federal prohibition and could offer hope to the 17 veterans who die by suicide every day.
Researchers in San Antonio have successfully treated combat PTSD in 85% of patients using magnetic brain stimulation alongside therapy. The breakthrough offers hope to millions of veterans and active-duty service members living with severe trauma.
President Trump signed an executive order to speed up research and potential FDA approval of psychedelic therapies for veterans suffering from PTSD, depression, and addiction. While the move brings hope to those who've exhausted traditional treatments, experts emphasize these therapies still need rigorous testing in controlled settings.
President Trump signed an executive order directing the FDA to expedite review of psychedelic drugs showing promise for veterans suffering from PTSD, depression, and traumatic brain injuries. One treatment already shows an 80-90% reduction in symptoms within one month.
A new executive order cuts red tape for scientists studying psychedelic compounds like MDMA and psilocybin as treatments for depression, PTSD, and addiction. The breakthrough also includes $50 million for research into ibogaine, a powerful substance showing promise for opioid addiction.
President Trump signed an executive order directing federal agencies to speed up approval of psychedelic therapies for PTSD, backed by $50 million in new research funding. The move could bring relief to millions of veterans and trauma survivors as soon as this summer.
President Trump signed an executive order to speed FDA review of psychedelic treatments showing 80-90% reduction in PTSD symptoms among veterans. The breakthrough therapy could help over 6,000 veterans who die by suicide each year.
President Trump will sign an executive order Saturday to advance research into psychedelics like psilocybin and ibogaine for therapeutic use. The move could open doors for controlled access to these promising mental health treatments.
A groundbreaking study shows that adding robotic-guided magnetic brain stimulation to therapy dramatically reduced combat PTSD symptoms in 85% of military personnel and veterans. The treatment could help up to 500,000 service members suffering from this debilitating condition.
Veterans with combat PTSD saw significant symptom reduction using MRI-guided brain stimulation in a clinical trial. This non-invasive treatment could offer new hope for those who haven't found relief with traditional therapy.
A breakthrough brain stimulation technique combined with therapy helped 85% of military personnel dramatically reduce PTSD symptoms in just 30 days. This precision treatment offers new hope for veterans who haven't found relief with traditional methods.
Showing 20 of 28